4.7 Article

What can pluripotent stem cells teach us about neurodegenerative diseases?

Journal

NATURE NEUROSCIENCE
Volume 13, Issue 7, Pages 800-804

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nn.2577

Keywords

-

Categories

Funding

  1. US National Institutes of Health [AG021617, NS042269, NS062180, NS064191, NS38370, NS058502, NS055923]
  2. US Department of Defense [W81XWH-08-1-0522, W81XWH-08-1-0465, DAMD 17-03-1]
  3. Parkinson Disease Foundation (New York)
  4. Thomas Hartman Foundation For Parkinson's Research
  5. A.L.S. foundation
  6. Muscular Dystrophy Association/Wings-over-Wall Street

Ask authors/readers for more resources

Neurodegenerative diseases represent a growing public health challenge. Current medications treat symptoms, but none halt or retard neurodegeneration. The recent advent of pluripotent cell biology has opened new avenues for neurodegenerative disease research. The greatest potential for induced pluripotent cells derived from affected individuals is likely to be their utility for modeling and understanding the mechanisms underlying neurodegenerative processes, and for searching for new treatments, including cell replacement therapies. However, much work remains to be done before pluripotent cells can be used for preclinical and clinical applications. Here we discuss the challenges of generating specific neural cell subtypes from pluripotent stem cells, the use of pluripotent stem cells to model both cell-autonomous and non-cell-autonomous mechanisms of neurodegeneration, whether adult-onset neurodegeneration can be emulated in short-term cultures and the hurdles of cell replacement therapy. Progress in these four areas will substantially accelerate effective application of pluripotent stem cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available